Acme United Q2 EPS USD 1.22

Acme United Corporation (NYSE American: ACU) reported second-quarter 2026 EPS of $1.22, according to available data. This figure reflects the company’s diluted EPS for the period ending June 30, 2026, and aligns with its historical performance trends. The company has demonstrated significant EPS volatility over the past decade, with notable peaks in 2023 and 2024, and a dip in 2022 following the sale of its Camillus and Cuda product lines.

For the first half of 2026, Acme United’s quarterly EPS averaged $0.99, with the June 2026 quarter showing a modest increase compared to the March 2026 quarter. The company’s EPS performance is influenced by its dual business segments—medical and consumer products—and is subject to fluctuations based on operational efficiency, cost management, and market demand.

Acme United has historically leveraged cost reduction initiatives and strategic divestitures to improve profitability. In 2023, the company reported a significant gain from the sale of the Camillus and Cuda product lines, which contributed to a sharp rise in EPS for that year. While the second-quarter 2026 EPS does not reflect a similar one-time gain, it indicates continued operational stability and consistent earnings generation.

Investors should consider the broader context of Acme United’s financial performance, including its gross margin improvements and free cash flow generation, when evaluating the significance of the Q2 2026 EPS result.